Canaccord upgraded Mayne Pharma to Buy from Hold with a price target of A$6.69, up from A$3.80, after the company released its first half results. Positive trends across all segments are continuing and new management is well proving its ability to execute and to restore investor confidence in the longer-term sustainable growth story, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>